<DOC>
	<DOCNO>NCT00291005</DOCNO>
	<brief_summary>- To evaluate overall tumor response rate subject metastatic hormone refractory prostate cancer - To evaluate PSA ( tumor marker ) response rate - To evaluate safety</brief_summary>
	<brief_title>PhII One Label Non-Comparative Trial Metastatic Hormone Refractory Prostate Cancer Combination With Prednisolone</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<criteria>Men prostate adenocarcinoma least one metastatic lesion measurable progress prior hormonal therapy . 1.Body temperature &gt; 38 degree centigrade . 2.Prior radiotherapy &gt; 25 % bone marrow . 3.Prior isotope therapy and/or brachytherapy 4.Prior gene therapy . 5.Active double cancer . 6.Known brain leptomeningeal involvement . 7.History hypersensitivity reaction drug 8.Other serious illness medical condition 9.Subjects investigator consider inappropriate social medical aspect .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>HRPC</keyword>
	<keyword>AIPC</keyword>
	<keyword>Hormone refractory</keyword>
	<keyword>Androgen independent</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Taxotere</keyword>
	<keyword>prednisolone</keyword>
</DOC>